Market Overview

Obalon Management Takes Advantage Of 200% Rally, Announces $3M Offering

Share:
Obalon Management Takes Advantage Of 200% Rally, Announces $3M Offering

Medical technology company Obalon Therapeutics Inc. (NASDAQ: OBLN) announced Thursday that it has entered into definitive agreements with investors for the purchase and sale of 5 million shares of common stock valued at $3 million.

Obalon shares were trading down 38.85 percent at 80 cents per share at the time of publication Thursday. 

The firm said it has entered into definitive agreements with investors for the purchase and sale of five million shares of common stock, par value .001 cents per share, at an offering price of 60 cents per share, pursuant to a registered direct offering.

Obalon Therapeutics said it offers the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity.

The closing of the registered direct offering is expected to take place on or about May 28 subject to the satisfaction of customary closing conditions, according to Obalon. 

Related Links: 

The Daily Biotech Pulse: Breakthrough Therapy Designation For Iovance, Guardant Prices Offering, 2 Stocks to Debut

Ideaya Biosciences IPO: What You Need To Know

Posted-In: News Offerings Best of Benzinga

 

Related Articles (OBLN)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

One-Third Of Worldwide Cannabis Users Stay In Africa

Brexit, China Fears Both Appear To Weigh On Market Early Despite Strong Best Buy Results